Nadine Hein

Novel RNA Polymerase I and Cyclin Dependent Kinase combination therapy for the treatment of aggressive Acute Myeloid Leukemia.

This paper identifies a synergistic combination of RNA Polymerase I inhibitor CX-5461 and CDK inhibitor Dinaciclib that enhances therapeutic efficacy in AML by inducing nucleolar stress and cell cycle arrest.

Integrated analysis of ribosomal DNA copy number and methylation using nanopore long-read sequencing

RICO quantifies rDNA copy number and methylation using nanopore sequencing, showing accurate results in simulations and human samples, with biological validation in mouse models.

Treatment with the ribosome biogenesis inhibitor CX-5461 increases platelet count in humans and enhances murine megakaryopoiesis

The paper shows that CX-5461, a ribosome biogenesis inhibitor, increases platelet counts in humans and enhances megakaryopoiesis in mice without affecting platelet function or inflammatory cytokines.

The novel RNA polymerase I transcription inhibitor PMR-116 exploits a critical therapeutic vulnerability in a broad-spectrum of high MYC malignancies.

This study shows PMR-116, a second-generation RiBi inhibitor, effectively targets high-MYC cancers without causing DNA damage, suggesting RiBi as a viable cancer therapy.

Biochemical-free enrichment or depletion of RNA classes in real-time during direct RNA sequencing with RISER

RISER enables real-time RNA class enrichment or depletion during direct RNA sequencing, improving detection of low-abundance RNAs by reducing dominant RNA reads.

Profiling age and body fluid DNA methylation markers using nanopore adaptive sampling

This study uses nanopore adaptive sampling to profile age and body fluid DNA methylation markers, identifying new age-correlated sites and validating known markers.